Penumbra (PEN) is in focus after recent trading data showed the stock at $324.37 as of August 24, 2026, with a year-to-date total return of 4.8% and a 1-year total return of 21.9%.

Across recent months Penumbra’s share price has inched higher, with a 30 day share price return of 1.8% and a 90 day share price return of 1.3%, while the 1 year total shareholder return of 21.9% points to momentum that has been building over a longer horizon.

Scan other fast moving healthcare opportunities with resilient balance sheets by reviewing our hand picked list of solid balance sheet and fundamentals (51 results) alongside Penumbra's recent performance.

After a strong 1 year total return and a share price near recent highs, the key question for Penumbra is valuation. Is most of the upside already reflected, or is the market still cautious about its potential?

Most Popular Narrative: 10.7% Undervalued

The most followed narrative puts Penumbra’s fair value at about $363 per share, above the recent $324.37 close. That gap is built on specific product and trial expectations rather than broad market optimism.

The soon-to-be-released STORM-PE randomized trial is poised to provide Level 1 evidence comparing Penumbra's thrombectomy technology to standard anticoagulation for pulmonary embolism, a positive outcome could expand guideline adoption, significantly accelerate procedure volumes, and drive substantial revenue growth by rapidly increasing penetration in a very underpenetrated, large market.

Want to see what sits behind that fair value for Penumbra? The narrative focuses on expectations for faster top line expansion, rising margins and a richer earnings multiple. It also raises questions about which exact targets have been incorporated and the time horizon over which this momentum is assumed to persist.

Result: Fair Value of $363 (UNDERVALUED)

However, the Penumbra narrative also depends on successful execution in key trials and product launches, while rising competition and higher spending could pressure margins and growth expectations.

Another View on Penumbra’s Valuation

While the popular Penumbra narrative points to a fair value of about $363 per share, the current pricing implies a rich P/E of 79.6x. That is well above the US Medical Equipment industry at 27.4x, the peer average at 24.9x, and a fair ratio of 29.4x that the market could move towards. If sentiment cools or forecasts change, how quickly could that gap close?

To see what the numbers say about this price in more detail, take a look at the valuation breakdown for Penumbra, starting with the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

If this Penumbra story feels optimistic, now is a good time to review the data yourself and decide how much upside you see. To understand what is driving that optimism, take a closer look at the 2 key rewards.

Looking for more investment ideas beyond Penumbra?

If Penumbra has caught your attention, do not stop here. Broaden your watchlist with ideas that match your style and keep your capital working intelligently.

• Target potential mispricings by reviewing companies on our 49 high quality undervalued stocks before the crowd catches up.
• Build a steadier core by scanning income focused opportunities through the 12 dividend fortresses that align with your risk tolerance.
• Strengthen your defensive side by checking companies with healthier finances using the 74 resilient stocks with low risk scores while conditions still look favourable.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.